ADAPY · Adaptimmune Therapeutics PLC
$0.03
+0.01 (+22.81%)
At close · Aug 28
Going-concern doubt
— flagged Aug 13, 2025
Substantial doubt about the company's ability to continue as a going concern.
“the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern within one year after the date the financial statements are issued.”View the 10-Q filed Aug 13, 2025
Market Cap
$44.53M
Shares
1.59B
Adaptimmune Therapeutics PLC Earnings Call Transcripts
Quarterly earnings calls for Adaptimmune Therapeutics PLC (ADAPY), with available speaker-labelled transcripts, captured audio replays, call highlights, 8-K earnings releases and periodic filings. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▲516.5%
$3.10M
−$39.07M
'21 Q2
21-08-09
▲0.8%
$1.20M
−$42.40M
'21 Q3
21-11-04
▼5.7%
$1.42M
−$38.86M
'21 Q4
22-03-14
▲723.7%
$3.58M
−$50.27M
'22 Q1
22-05-09
▲78.9%
$5.54M
−$44.52M
'22 Q2
22-08-04
▲482.5%
$7.01M
−$41.42M
'22 Q3
22-11-08
▲678.3%
$11.03M
−$29.25M
'22 Q4
23-03-06
▲1231.5%
$47.60M
$1.04M
'23 Q1
23-05-12
▼7.4%
$5.13M
−$21.39M
'23 Q2
23-08-09
▲4.5%
$7.32M
−$45.60M
'23 Q3
23-11-08
▼97.9%
$231,000
−$47.92M
'23 Q4
24-03-06
▼88.1%
$5.68M
−$48.50M
'24 Q1
24-05-15
▲2399.6%
$128.23M
$69.52M
'24 Q2
24-08-12
▲458.8%
$40.90M
−$17.62M
'24 Q3
24-11-13
▲1294.8%
$3.22M
−$74.22M
'24 Q4
25-03-20
LATEST
▲28.3%
$7.29M
−$47.58M
'25 Q1
25-05-13
Earnings call
FY25 · Q1
2025-05-13
Adaptimmune Therapeutics PLC (ADAPY) Q1 2025 Earnings Call
Revenue
$7.29M
▲ 28.3% YoY Diluted EPS
$-0.03
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-03-20
Adaptimmune Therapeutics PLC (ADAPY) Q4 2024 Earnings Call
Revenue
$3.22M*
▲ 1294.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-13
Adaptimmune Therapeutics PLC (ADAPY) Q3 2024 Earnings Call
Revenue
$40.90M
▲ 458.8% YoY Diluted EPS
$-0.01
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-12
Adaptimmune Therapeutics PLC (ADAPY) Q2 2024 Earnings Call
Revenue
$128.23M
▲ 2399.6% YoY Diluted EPS
$0.04
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-15
Adaptimmune Therapeutics PLC (ADAPY) Q1 2024 Earnings Call
Revenue
$5.68M
▼ 88.1% YoY Diluted EPS
$-0.03
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-03-06
Adaptimmune Therapeutics PLC (ADAPY) Q4 2023 Earnings Call
Revenue
$231,000*
▼ 97.9% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-08
Adaptimmune Therapeutics PLC (ADAPY) Q3 2023 Earnings Call
Revenue
$7.32M
▲ 4.5% YoY Diluted EPS
$-0.03
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-09
Adaptimmune Therapeutics PLC (ADAPY) Q2 2023 Earnings Call
Revenue
$5.13M
▼ 7.4% YoY Diluted EPS
$-0.02
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-12
Adaptimmune Therapeutics PLC (ADAPY) Q1 2023 Earnings Call
Revenue
$47.60M
▲ 1231.5% YoY Diluted EPS
$0.00
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-03-06
Adaptimmune Therapeutics PLC (ADAPY) Q4 2022 Earnings Call
Revenue
$11.03M*
▲ 678.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-08
Adaptimmune Therapeutics PLC (ADAPY) Q3 2022 Earnings Call
Revenue
$7.01M
▲ 482.5% YoY Diluted EPS
$-0.04
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-04
Adaptimmune Therapeutics PLC (ADAPY) Q2 2022 Earnings Call
Revenue
$5.54M
▲ 78.9% YoY Diluted EPS
$-0.05
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-09
Adaptimmune Therapeutics PLC (ADAPY) Q1 2022 Earnings Call
Revenue
$3.58M
▲ 723.7% YoY Diluted EPS
$-0.05
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-03-14
Adaptimmune Therapeutics PLC (ADAPY) Q4 2021 Earnings Call
Revenue
$1.42M*
▼ 5.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-04
Adaptimmune Therapeutics PLC (ADAPY) Q3 2021 Earnings Call
Revenue
$1.20M
▲ 0.8% YoY Diluted EPS
$-0.05
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-09
Adaptimmune Therapeutics PLC (ADAPY) Q2 2021 Earnings Call
Revenue
$3.10M
▲ 516.5% YoY Diluted EPS
$-0.04
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-06
Adaptimmune Therapeutics PLC (ADAPY) Q1 2021 Earnings Call
Revenue
$434,000
▼ 43% YoY Diluted EPS
$-0.04
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-02-25
Adaptimmune Therapeutics PLC (ADAPY) Q4 2020 Earnings Call
Revenue
$1.50M*
▲ 106.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-11-05
Adaptimmune Therapeutics PLC (ADAPY) Q3 2020 Earnings Call
Revenue
$1.19M
▲ 403.4% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-08-06
Adaptimmune Therapeutics PLC (ADAPY) Q2 2020 Earnings Call
Revenue
$502,000
▲ 219.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-05-14
Adaptimmune Therapeutics PLC (ADAPY) Q1 2020 Earnings Call
Revenue
$761,000
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-02-27
Adaptimmune Therapeutics PLC (ADAPY) Q4 2019 Earnings Call
Revenue
$728,000*
▼ 50.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Showing 1–22 of 22 earnings calls